Section Editor(s): Cooper, David; Lange, Joep M. A.; Montaner, Julio S. G.
Highly active antiretroviral therapy (HAART) has led to significant reductions in HIV morbidity and mortality. HAART is a combination of at least three antiretroviral (ARV) drugs: a protease inhibitor (PI) and/or a nonnucleoside analog reverse transcriptase inhibitor (NNRTI) and one or two nucleoside analog reverse transcriptase inhibitors (NRTI). HAART is not a cure for HIV infection, however, and so currently requires permanent and continuous administration (1). There is an increasing focus on the adverse effects associated with HAART. In addition to numerous relatively acute complications, such as hepatitis, neuropathy, hypersensitivity, and pancreatitis, there is growing concern regarding risk factors for cardiovascular disease (CVD) observed in patients receiving HAART; these include hypercholesterolemia, hypertriglyceridemia, low high-density lipoprotein (HDL) cholesterol, and insulin resistance/type 2 diabetes mellitus (2). As CVD is the commonest cause of death in the developed world (3), even a small increase in CVD risk with HAART may lead to significant changes in morbidity and mortality in HIV-infected adults. For similar reasons, it is difficult to determine conclusively whether HAART leads to an increased incidence of CVD.
This paper outlines recent data relating to the prevalence and pathogenesis of CVD risk factors in HIV-infected adults, as well as various potential treatment options.
CVD RISK FACTORS IN HIV-INFECTED ADULTS
A large number of cross-sectional studies and a smaller number of prospective studies in HIV-infected and uninfected adults have consistently demonstrated an increased prevalence of dyslipidemia associated with HAART (2,4-12). Abnormalities in lipid profiles appear to be relatively stable over time if the HAART regimen is unchanged (4). Most PIs, with the possible exceptions of saquinavir and atazanavir, increase plasma levels of both total and low density lipoprotein (LDL) cholesterol, as well as levels of triglycerides (Table 1) (13-15). Prospective data on high density lipoprotein (HDL) cholesterol plasma levels in patients being treated with PIs alone or PI-based HAART are unclear, perhaps because studies were under-powered to assess this endpoint. As HIV infection per se suppresses HDL cholesterol, it would be reasonable to expect a HAART that suppresses HIV replication would also lead to increases in HDL cholesterol. The only ARV agent shown to raise the HDL cholesterol plasma level (which is the greatest single predictor of CVD risk) in a randomized study is nevirapine administered with two NRTIs, whereas PI-based HAART is associated with stable or declining HDL cholesterol levels over time (16-19). Efavirenz appears to have variable effects on plasma levels of both HDL cholesterol and triglycerides, while significantly increasing total cholesterol levels (20).
The largest study of cardiovascular risk is the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study; it was initiated in 1999 to determine whether HAART increases the rate of CVD (21). Analysis of baseline data from over 17,000 subjects found that the proportion of patients with dyslipidemia likely to incur increased CVD risk grew as the number of ARV classes in their regimens increased. Additional parameters independently associated with the presence of all forms of dyslipidemia were increasing age and clinically diagnosed lipodystrophy. One of the more novel findings was that NNRTI-based HAART was associated with a lower prevalence of low HDL cholesterol levels than PI-based HAART or no ARV therapy. Other cardiovascular risk factors were also relatively common in the D:A:D cohort, particularly smoking (52%), a positive family history of CVD (12%), and hypertension (8%) (Figure 1).
Diabetes Mellitus and Insulin Resistance
Insulin resistance and type 2 diabetes mellitus are also significantly associated with HAART (2,4-6,8-10,12,22,23). The D:A:D study identified diabetes mellitus in 2.5% of patients, a prevalence probably no greater than in the general population. Like most other studies of HIV-infected adults, D:A:D, however, used only fasting glucose to assess glucose tolerance. Use of the more sensitive oral glucose tolerance test identified diabetes in approximately 8-10% of patients taking PI-based HAART, and impaired glucose tolerance in a further 15% of patients (4,22). These studies, as well as D:A:D, demonstrated that abnormal glucose tolerance was significantly associated with current use of PI therapy (but not PI type or duration) as well as increasing age and the presence of clinically diagnosed lipodystrophy. An association between insulin resistance and lipoatrophy is not surprising, as insulin resistance is typical of congenital lipoatrophy and also of central adiposity (syndrome X) (24).
There are less data regarding the direct effects of PIs on glucose metabolism as compared with lipid metabolism. However, indinavir has been shown to increase insulin resistance in non-HIV-infected adults after a single dose (as do saquinavir and nelfinavir in vitro), whereas nelfinavir and amprenavir have not been found to affect insulin sensitivity in vivo (25,26). NRTIs have not been shown to affect lipid or glucose metabolism directly (although this has not been definitively studied) but NRTIs are strongly associated with insulin resistance in patients with lipoatrophy, even in the absence of PI therapy (5,6). There are no published data on the effects of NNRTIs on glucose metabolism.
Pathogenesis of HAART-Related Dyslipidemia and Insulin Resistance
The pathogenesis of dyslipidemia and insulin resistance in HIV-infected adults receiving HAART is complex (Figure 2). PIs affect multiple metabolic pathways, including those involving sterol regulatory enhancer binding protein type-1 (SREBP-1), GLUT-4 and the proteasome with adverse effects on adipocyte growth, insulin signaling and hepatocyte cholesterol synthesis, respectively (27-29). NRTIs are associated with mitochondrial toxicity, lactic acidemia and lipoatrophy (5,6). As mentioned above, lipoatrophy results in leptin deficiency that enhances insulin resistance. Central fat accumulation may also exacerbate insulin resistance, as is seen in syndrome X. Why only some insulin-resistant individuals become diabetic is unknown, although type 2 diabetes in the general population tends to be associated with both reduced insulin secretion and reduced insulin sensitivity. Age and gender are non-treatment factors that are likely to have additional effects.
Estimating Cardiovascular Risk
What is the estimated risk of CVD in patients receiving HAART? The increase in CVD risk with HAART has been estimated, from available lipid and glycemic data using the Framingham equation, to be 1.4 cardiac events per thousand years of PI-based HAART (30). Importantly, if the Framingham equation does apply in this setting, any risks will also depend on the presence and severity of all cardiac risk factors (smoking, hypertension, left ventricular failure, age, dyslipidemia, diabetes) (31). HIV-uninfected patients who have hypercholesterolemia, hypertriglyceridemia and diabetes are at a fivefold higher risk of CVD than those with none of these risk factors (32). There is no biological reason to suspect that HIV-infected adults will not incur similar CVD risk from similar risk factors as HIV-uninfected adults, provided HIV suppression is effective and AIDS is prevented over an extended period.
The CVD risk associated with HAART can also be estimated by calculating the number of patients that need to be treated with a therapy (i.e. HAART) in order for one additional patient to be harmed by that therapy, i.e., the number treated to harm (NNTH) (31). For example, it has been estimated that a male, 50-year-old smoker who receives PI-based HAART for 10 years has a 13% excess risk of ischemic heart disease (IHD). Therefore, one case of IHD will occur for every 7 patients treated with PI-based HAART (NNTH = 7) (Table 2). The 10-year risk was estimated to be similar or even higher for 50-year-old women who smoke (NNTH = 6).
These risks of developing CVD should of course also be balanced against the risks of not treating HIV-infected patients. This is illustrated by two assessments of the risk of developing AIDS over 3 years with either no treatment or HAART (31,33). Patients with low CD4 cell counts and high plasma viral loads were at considerable risk of developing AIDS in the absence of treatment, but those with CD4 cell counts >350 cells/mm3 did not appear to have derived significant reduction in AIDS risk.
Cardiovascular Disease and HAART
Does this perceived risk translate into increased numbers of CVD cases? Several cohort studies have investigated the effects of HAART on CVD incidence. CVD events that have been evaluated include IHD, myocardial infarction (MI) and carotid intima medial thickness (IMT), a known surrogate marker of CVD. HIV-infected patients, with or without HAART, with greater carotid IMT were more likely to be male, older, smokers and to have hypercholesterolemia (34-36). Neither HIV infection nor PI use was significantly associated with greater IMT but, as PIs increase cholesterol, it would be premature to state that there is no adverse effect of PI-based HAART on IMT.
Clinical outcome data estimating CVD risk in relation to the class of ARV therapy are not conclusive. A retrospective study of 36,766 American HIV-infected veterans followed for up to 8 years found no relationship between the increasing use of PIs, NNRTIs or NRTIs and cardiovascular or cerebrovascular morbidity or mortality (37). A further study indicated that PI usage was not associated with an increased risk of CVD events, although HIV infection itself did appear to be a risk factor (38). In contrast, a French study involving 19,795 men concluded that PI therapy was associated with an increased risk of MI, an effect that was proportional to the duration of PI therapy (39).
Treating Cardiovascular Risk
In the light of the information linking HAART to an increased risk of CVD, the focus is now on developing interventions that reduce this risk. In non-HIV-infected adults, effective strategies are smoking cessation, treatment of hypertension, weight reduction and exercise. The latter two strategies are associated with increasing HDL cholesterol levels and reductions in insulin resistance, total cholesterol and triglyceride levels.
Given the relative risks of AIDS without HAART and of CVD with HAART, factors that would affect a decision to treat dyslipidemia or diabetes would include: their severity; presence of CVD symptoms; HIV disease status; the likelihood that a particular HAART regimen would be long-term; and the presence of other CVD risk factors. Nevertheless, it should be remembered that the efficacy and safety of metabolic interventions designed to prevent CVD cannot be extrapolated at this time from studies of healthy adults. It may be that non-HIV lipodystrophy is a more relevant model, in which lipid-lowering and diabetic therapies tend to be far less effective, likely because of the lipoatrophy and central obesity that underlie these disorders.
In HIV-infected adults, increased exercise can reduce central fat accumulation, but at the expense of increased peripheral fat wasting, and was not found to affect any metabolic parameter (40). No dietary intervention has been evaluated. In a randomized, placebo-controlled study, gemfibrozil resulted in modest reduction in triglyceride plasma levels, but no change in cholesterol levels, and appeared to be safe (41). Fluvastatin and pravastatin produced a significant reduction in cholesterol plasma levels in HIV-infected patients with hypercholesterolemia, but failed to affect triglyceride plasma levels or initiate any change in endothelial reactivity, even though this has been reported in non-HIV-infected patients (42,43). Metformin effectively improves insulin sensitivity and reduces visceral adiposity, without appearing to aggravate lactic acidemia (44).
Since PI therapy appears to incur a higher risk of CVD than NNRTIs or NRTIs, one strategy has been to switch from a PI to either a NNRTI- or NRTI-based therapy. To date, switching to nevirapine or abacavir (or both) leads to reductions in plasma levels of triglycerides and total cholesterol within 4 to 12 weeks (20,45-49). Total cholesterol levels did not fall consistently in patients who were switched to efavirenz-based regimens. While insulin resistance improved in some patients who switched to efavirenz or nevirapine, switching to abacavir has not been well studied, and improvement has not been demonstrated for patients with ongoing lipoatrophy (25,26). It is also unclear whether any lipid or glycemic parameter normalizes after switching from a PI-based regimen. Reported studies have only been conducted over periods of 6 to twelve months and longer follow-up periods may provide more conclusive data and an indication of whether these differences will translate into a differential risk of CVD.
HAART-associated dyslipidemia and insulin resistance are common and persistent, particularly in PI-treated patients. The pathogenesis of these metabolic abnormalities is not clearly understood but involves direct PI effects, lipodystrophy and non-treatment related factors. These seem likely, but are not proven, to incur an increased risk of CVD.
The most effective strategies for dyslipidemia appear to be PI switching to nevirapine or adding statins to the regimen; the best strategy for diabetes is less clear but may be PI switching or metformin administration. As in other areas of medicine, the risk:benefit ratio of HAART should be assessed prior to initiating and changing treatment regimens and all risk factors for CVD, particularly for IHD, reduced as much and as safely as possible. Any primary prevention for dyslipidemia or diabetes should incur minimal risk (in terms of both side effects and ARV failure) and be targeted to those with greater CVD risk.
1. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available at: http://hivatis.org/trtgdlns.html#Adult
. Accessed 11 June 2002.
2. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-F58.
3. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world. Global burden of disease study. Lancet 1997;349:1269-1276.
4. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999;353:2093-2099.
5. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999;13:1659-1667.
6. Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000;14:F25-F32.
7. Boubaker K, Sudre P, Flepp M, et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis 2001;33:1931-1937.
8. Thiebaut R, Daucourt V, Mercie P, et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Clin Infect Dis 2000;31:1482-1487.
9. Heath K, Hogg RS, Chan KJ, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 2001;15:231-240.
10. Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001;357:592-598.
11. Bogner JR, Vielhauer V, Beckmann RA, et al. Stavudine versus zidovudine and the development of lipodystrophy. JAIDS 2001;27:237-244.
12. Hadigan C, Meigs J, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001;32:130-139.
13. Purnell J, Zambon A, Knopp R, et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000;14:51-57.
14. Haas DW, Zala C, Schrader S, et al. Atazanavir plus saquinavir once daily favorably affects total cholesterol (TC), fasting triglyceride (TG), and fasting LDL cholesterol (LDL) profiles in patients failing prior therapy (trial AI424-009, week 48) [abstract 42]. Presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, U.S.A., 24-28 February 2002.
15. Dragsted UB, Benetucci J, Bruun JN, on behalf of the MaxCmin1 Trial Group. A Phase IV randomised, open label, multicentre trial to evaluate safety and efficacy of indinavir/ritonavir (800/100 mg BID) vs. saquinavir/ritonavir (1000/100 mg BID) in adult HIV-1 infection [abstract 010]. Presented at the 8th European Conference on Clinical Aspects and Treatment of HIV Infection, Athens, Greece, 28-31 October 2001.
16. Miller GJ, Miller NE. Plasma HDL concentrations and development of ischaemic heart disease. Lancet 1975;1:16-19.
17. Gordon T, Castelli WP, Hjortland MC, et al. HDL as a protective factor against coronary heart disease: the Framingham study. Am J Med 1977;62:707-714.
18. Kannal WB, Dawber TR, Kagan A, et al. Factors of risk development of coronary heart disease: six year follow-up: the Framingham Study. Ann Intern Med 1961;55:33-50.
19. van der Valk M, Kastelein JJP, Murphy RL, et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001;15:2407-2414.
20. Saag MS, Powderly WG, Schambelan M, et al. Switching antiretroviral drugs for treatment of metabolic complications in HIV-1 infection: summary of selected trials. Topics HIV Med 2002;10:47-49.
21. van Leth F, Friis-Møller N, Weber R, et al. Distinguishable lipid profiles between PI and NNRTI therapy may carry different risk of cardiovascular disease (CVD) [abstract 34]. Presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, U.S.A., 24-28 February 2002.
22. Walli R, Herfort O, Michl GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired glucose tolerance in HIV-1-infected patients. AIDS 1998;12:F167-F174.
23. Yarasheski KE, Tebas P, Sigmund C, et al. Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquir Immun Defic Syndrom 1999;21:209-216.
24. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-359.
25. Noor MA, Seneviratne T, Aweeka FT, et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 2002;16:F1-F8.
26. Rudich A, Vanounou S, Riesenberg K, et al. The HIV protease inhibitor nelfinavir induces insulin resistance and increases basal lipolysis in 3TC-L1 adipocytes. Diabetes 2001;50:1425-1431.
27. Caron M, Auclair M, Vigouroux C, et al. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 2001;50:1378-1388.
28. Liang JS, Distler O, Cooper DA, et al. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med 2001;7:1327-1331.
29. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000;275:20251-20254.
30. Grunfeld C. Disturbances in lipid metabolism due to HIV infection and its therapy [abstract S3]. Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, U.S.A., February 1999.
31. Egger M, Janghans C, Friis-Moller N, et al. Highly active antiretroviral therapy and coronary heart disease: the need for a perspective. AIDS 2001;15(suppl 5):S193-S201.
32. The Caerphilly and Speedwell Collaborative Group. Caerphilly and Speedwell collaborative heart disease study. J Epidemiol Comm Hlth 1994;38:259-260.
33. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-954.
34. Depairon M, Chessex S, Sudre P, et al. Premature atherosclerosis in HIV-infected individuals: focus on protease inhibitor therapy. AIDS 2001;15:329-334.
35. Seminari E, Pan A, Voltini G, et al. Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors. Atherosclerosis 2002;162:433-438.
36. Mercie P, Thiebaut R, Lavignolle V, et al. Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement. Ann Med 2002;34:55-63.
37. Bozzette SA, Ake CF, Tam HK, et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003;348:702-10.
38. Klein D, Hurley L, Sorel M, Sidney S. Do protease inhibitors increase the risk for coronary heart disease among HIV positive patients? - Follow-up through June 2000 [abstract 655]. Presented at the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, U.S.A., 4-8 February 2001.
39. Mary-Krause M, Cotte L, Partisani M, et al. Impact of treatment with protease inhibitor on myocardial infarction occurrence in HIV-infected men [abstract 657]. Presented at the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, U.S.A., 4-8 February 2001.
40. Roubenoff R, Weiss L, McDermott A, et al. A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution. AIDS 1999;13:1373-1375.
41. Miller J, Brown D, Amin J, et al. A randomised, double-blind study of gemfibrozil (GF) for the treatment of protease inhibitor-associated hypertriglyceridaemia. AIDS 2002;16:2195-2200.
42. Mooser V. Atherosclerosis and hyperlipidaemia in the HAART era [plenary lecture]. Presented at the 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Athens, Greece, October 2001.
43. Moyle GJ, Lloyd M, Reynolds B, et al. Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy. AIDS 2001;15:1503-1508.
44. Hadigan C, Corcoran C, Basgoz N, et al. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA 2000;284:472-477.
45. Martinez E, Conget I, Lozano L, et al. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999;13:805-810.
46. Martinez E, Garcia-Viejo MA, Blanco JL, et al. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. Clin Infect Dis 2000;31:1266-1273.
47. Walli R, Huster K, Bogner JR, et al. Switching from protease inhibitors to abacavir improves insulin sensitivity and fasting lipids: 12 month follow-up [abstract 672]. Presented at the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, U.S.A., February 2001.
48. Ruiz L, Negredo E, Domingo P, et al. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy. JAIDS 2001;27:229-236.
49. Carr A, Hudson J, Chuah J, et al. HIV protease inhibitor substitution in patients with lipodystrophy: a randomised, multicentre, open-label study. AIDS 2001;15:1811-1822.
This publication has been made possible by an educational grant from Boehringer Ingelheim.
© 2003 Lippincott Williams & Wilkins, Inc.